Description: Ziccum AB (publ) develops dry powder preparations of biological pharmaceuticals. It develops and commercializes LaminarPace, a spray drying technology that dries liquid biopharmaceuticals, such as vaccines or protein therapeutics into a particle engineered powder product. The company was incorporated in 2017 and is headquartered in Lund, Sweden.
Home Page: ziccum.com
Scheelevägen 22
Lund,
223 63
Sweden
Phone:
46 7 09 61 55 99
Officers
| Name | Title |
|---|---|
| Ms. Ann Gidner | Chief Exec. Officer |
| Ms. Frida Hjelmberg | Chief Financial Officer |
| Mr. Fabrice Rose | Scientific Director |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8073 |
| Price-to-Sales TTM: | 2382.5972 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 8 |